CANNPRISMA, a 100% Portuguese company, has, since today, official authorization to cultivate, process, import and export cannabis-based products for medicinal purposes, by the PSP and by INFARMED, the Portuguese government agency responsible to the Ministry of Health, which evaluates, authorizes, regulates and controls medicines for human use – including medical cannabis – as well as health products.
The cultivation and processing unit of CANNPRISMA, with 10 hectares, is located in the municipality of Castro Marim and «includes about 3000 square meters of greenhouses and support infrastructure with the latest technology, respecting all the required quality standards (accompanying whenever possible all GMP requirements) which allows to obtain high quality flower», stresses the company.
By the end of 2021, the construction of the factory is expected to be completed, as well as its authorization for GMP operation by INFARMED. This GMP manufacturing unit, located in Vila Real de Santo António, already has an aptitude decision from INFARMED.
The guaranteed authorization means that the entire activity of this Algarve company complies with the Good Agricultural and Collection Practices (GACP).
“The pandemic situation that has been going on since the beginning of last year has delayed the process of obtaining the definitive license, but which has now been concluded with the successful on-site inspection, by INFARMED”, reveals the company.
This licensing has already been subject to inspection by the Public Security Police, which confirmed compliance with all security rules, in accordance with current legislation (Ordinance No. 83/2021).
CANNPRISMA adds that its future pharmaceutical industry facilities to be created in Vila Real de Santo António, together with obtaining its definitive license, are in line with the “company's strategy of being present in the entire value chain of the cannabis business medicinal, as well as in the verticality of the company's business (R&D, cultivation and harvesting, drying, packaging, processing, extraction, crystallization API, drug manufacturing, bottling and labeling)».
It is because, he stresses, «Portugal currently has the best strategic conditions for the implementation of this new business area: climate, location, human resources, knowledge, policy, applicable legislation, among others».
There is "great potential to become a leading country in research, production and also as one of the largest exporters of medicinal cannabis in Europe".
«The rigor, quality, safety and clarity required by Portuguese licensing entities contribute in a definitive way so that Portugal becomes the best option for the cultivation and production of medicinal cannabis-based products for the whole world, still complying with all requirements in terms of business ethics», he also considers.
CANNPRISMA is a company present in the Canábis Medicinal market, being the first company with 100% Portuguese capital. Its aim is to become a world reference in Research and development, Cultivation, Harvesting, Drying, Processing, Extraction, Crystallization-API, Manufacture of medicines and packaging of medicinal cannabis.
All partners and employees share the social concern of becoming part of a value chain that supplies medicines, preparations or substances based on the Cannabis Sativa L. plant with a Premium quality.
CANNPRISMA has an experienced and qualified team in the agricultural and pharmaceutical industry, which has joined forces to realize a common dream: to provide products in the medical cannabis value chain, produced in a GMP environment, with premium and differentiated quality for a growing number of patients , which find relief in the therapeutic properties of the cannabis plant.
«Our performance in the market takes the community into account, acting reliably and honestly with all our partners and with the environment. We believe that we must be concerned with nature and with those around us, ensuring a sustainable and bright future for the next generations», guarantees the company.
Comments